Drug Trial Radar · NCT03475953
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
747
Planned (sponsor's estimate)
Start
May 4, 2018
Primary completion
Dec 31, 2024
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Institut BergoniéAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bayer; Merck KGaA, Darmstadt, Germany
- First posted
- Mar 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Assessment of the efficacy and safety of Regorafenib and Avelumab in patients with advanced or metastatic solid tumors (ten cohorts), once the Recommanded Phase II Dose (RP2D) has been determined (phase I trial). Assessement of the efficacy and safety of a low-dose of regorafenib (80mg/day) with avelumab in patients with advanced or metastatic colorectal tumors.
Conditions
- Colorectal Cancer Not MSI-H or MMR-deficient
- GIST
- Oesophageal or Gastric Carcinoma
- Biliary Tract Cancer
- Hepatocellular Carcinoma
- Soft-tissue Sarcoma
- Thyroid Cancer
- Gastro-enteropancreatic Neuroendocrine Tumor
- Non-small Cell Lung Cancer
- Solid Tumor, Adult
- Urothelial Carcinoma
- HPV-Related Carcinoma
- Triple Negative Breast Cancer
- Renal Carcinoma
- Mesotheliomas Pleural
Interventions
Phase 1 : RegorafenibDrug
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Patients will be allocated 3 dose levels of Regorafenib following a 3 + 3 design.
Phase 1 : AvelumabDrug
A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.). Avelumab will be administered on cycle 1 Day 15 as a 1-hour intravenous (IV) infusion (10mg/kg), repeated every two weeks thereafter (ie. Day 1 and Day 15 of each subsequent cycle, as a 1-hour intravenous infusion).
Phase 2 : RegorafenibDrug
Phase 2 : Regorafenib - All patients will be treated at the RP2D of regorafenib defined in the preliminary phase 1 trial with the same schedule as in the phase I.
Phase 2 : AvelumabDrug
Phase 2 : Avelumab - All patients will be treated with avelumab with the same schedule as in the phase 1 trial.
Phase 2: low-dose RegorafenibDrug
Phase 2 : Regorafenib - All patients will be treated at a fixed low-dose of regorafenib of 80 mg/day
Primary outcomes
What the sponsor says the trial is designed to measure.
- PHASE I : Recommended phase II dose (RP2D)Time frame: During the first cycle (28 days)
- PHASE II (7cohorts A, C, D, E, F and G) : Assessment of the antitumor activity of regorafenibTime frame: Throughout the treatment period, an average of 6 months
- Phase II (cohorts B, H, I, M, N, O and P): Assessment of the antitumor activity of regorafenibTime frame: 6 months
- Phase II (cohort A'): Assessment of the antitumor activity of regorafenibTime frame: 4 months
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Institut Bergonié
Bordeaux, France · Recruiting
Centre Hospitalier Régional Universitaire - CHU Morvan
Brest, France · Recruiting
Centre Léon Bérard
Lyon, France · Recruiting
Institut de Cancérologie de Montpellier
Montpellier, France · Recruiting
Institut Curie
Paris, France · Recruiting
IUCT Oncopôle - Institut Claudius Regaud
Toulouse, France · Recruiting
Institut Gustave Roussy
Villejuif, France · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.